JPH0471056B2 - - Google Patents

Description

[Detailed description of the invention]

INDUSTRIAL APPLICATION FIELD OF THE INVENTION The present invention relates to cardiotonic agents. Disclosure of the Invention The cardiotonic agent of the present invention contains an oxindole derivative represented by the following general formula (1) or a salt thereof as an active ingredient. [In the formula, A represents a lower alkylene group, and n represents 0 or 1. B is

[Reaction scheme-2]

[In the formula, R is the same as above. X ¹ represents a halogen atom. ] The reaction between the compound of general formula (3) and the piperazine derivative (2) is carried out without a solvent or in an inert solvent at room temperature to 200°C.
degree, preferably under temperature conditions of room temperature to 120°C, 1
It will be completed in about 24 hours. As an inert solvent,
For example, ethers such as dioxane, tetrahydrofuran, ethylene glycol dimethyl ether, and diethyl ether, aromatic hydrocarbons such as benzene, toluene, and xylene, lower alcohols such as methanol, ethanol, and isopropanol, dimethylformamide, dimethyl sulfoxide, and hexamethyl phosphoric acid. Polar solvents such as triamide, acetone, acetonitrile, etc. can be used. The above reaction is more advantageously carried out using a basic compound as a deoxidizing agent. The basic compound also includes the piperazine derivative itself used as a raw material, and if an excess amount of this is used, there is no need to use other basic compounds, but for example, potassium carbonate, sodium carbonate, sodium hydroxide, hydrogen carbonate, etc. Sodium, sodium amide, sodium hydroxide, triethylamine,
Tertiary amines such as tripropylamine, pyridine, quinoline, etc. can be used. The above reaction may be carried out by adding an alkali metal iodide compound such as potassium iodide or sodium iodide or hexamethylphosphoric acid triamide as a reaction promoter, if necessary. The ratio of the compound of general formula (3) and the piperazine derivative (2) in the above reaction is not particularly limited and is appropriately selected within a wide range, but usually the latter is used in equimolar to excess amounts, preferably in excess of the former. It is preferable that the amount is equimolar to 5 times the molar amount. Reaction formula-3 [In the formula, A and n are the same as above. R' is a lower alkanoyl group, a benzoyl group that may have 1 to 3 groups selected from the group consisting of lower alkyl groups, lower alkoxy groups, and halogen atoms as substituents on the phenyl ring, or a substituent on the phenyl ring. represents a benzoyl group that may have a lower alkylenedioxy group. X ² represents a hydroxyl group. ] That is, the compound represented by the above general formula (1e) is
It is produced by reacting a compound of general formula (1d) or a compound with its amino group activated with a compound of general formula (4) or a compound with its carboxy group activated. In the above reaction, an oxindole derivative represented by the general formula (1a) shown in the reaction scheme-1 or an activated compound of its carboxyl group and an amine represented by the general formula (2) or an activated compound of the amino group of It can be carried out under the same operation and conditions as the reaction. Reaction formula-4 [In the formula, R″ represents a lower alkyl group, phenoxy lower alkyl group, phenyl lower alkyl group, or benzoyl lower alkyl group. ^{X 3} is a halogen atom,
It represents a lower alkanesulfonyloxy group, an arylsulfonyloxy group, or an aralkylsulfonyloxy group. ] That is, the compound represented by the general formula (1f) is produced by reacting the compound represented by the general formula (1d) with the compound represented by the general formula (5). This reaction can be carried out under the same operation and conditions as the method of reacting the carboxylic acid halide with the amine (2) described above. In addition, in the compound represented by the above general formula (5 ⁾ , the halogen atom defined by Sulfonyloxy, ethanesulfonyloxy,
Examples include isopropanesulfonyloxy, propanesulfonyloxy, butanesulfonyloxy, tert-butanesulfonyloxy, pentanesulfonyloxy, and hexanesulfonyloxy groups,
Further, specific examples of the arylsulfonyloxy group include phenylsulfonyloxy, 4-methylphenylsulfonyloxy, 2-methylphenylsulfonyloxy, 4-nitrophenylsulfonyloxy, 4-methoxyphenylsulfonyloxy,
Examples include substituted or unsubstituted arylsulfonyl groups such as 3-chlorophenylsulfonyloxy and α-naphthylsulfonyloxy groups, and specific examples of aralkylsulfonyloxy groups include benzylsulfonyloxy and 2-phenylethylsulfonyloxy. , 4-phenylbutylsulfonyloxy, 4-methylbenzylsulfonyloxy, 2-
Examples include substituted or unsubstituted aralkylsulfonyloxy groups such as methylbenzylsulfonyloxy, 4-nitrobenzylsulfonyloxy, 4-methoxybenzylsulfonyloxy, 3-chlorobenzylsulfonyloxy, and α-naphthylmethylsulfonyloxy. In the reaction scheme-1 detailed above, the general formula (1a) used for the production of the compound of the general formula (1b)
For example, the compound represented by the following reaction scheme -5 or -6
It can be manufactured by the method shown below. Reaction formula-5 [In the formula, X ¹ is the same as above. R ³ represents an aromatic amine residue. ] In the above, the reaction to obtain the compound of general formula (8) can be carried out by reacting the compound of general formula (6) with aromatic amine (7) in a suitable solvent or in the absence of a solvent. Any solvent can be used as long as it does not affect the reaction, such as halogenated hydrocarbons such as methylene chloride, chloroform, and dichloromethane, ethers such as diethyl ether, tetrahydrofuran, and dimethoxyethane, and acetic acid. Examples include esters such as methyl and ethyl acetate, aprotic polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, and hexamethylphosphoric triamide. Examples of aromatic amines include pyridine and quinoline. The amount of the aromatic amine used is determined by the general formula (6)
It is preferable to use at least an equimolar amount, preferably a large excess amount, based on the compound. The reaction temperature is 50~
The temperature is 200℃, preferably 70-150℃, and the reaction temperature is 1-150℃.
Finished in 10 hours. The hydrolysis reaction of the compound of general formula (8) obtained above can be carried out using an inorganic base such as sodium hydroxide or potassium hydroxide or hydrochloric acid or hydrobromic acid in water or an alcohol such as methanol or ethanol. Room temperature ~150 using acid
The process takes about 10 minutes to 10 hours. Reaction formula-6 [X ¹ is the same as above. ] The reaction between the compound of general formula (9) and a halogen is usually carried out in a solvent. Examples of solvents that can be used include ethers such as tetrahydrofuran and dioxane, carboxylic acids such as acetic acid and propionic acid, aromatic hydrocarbons such as benzene, dimethylformamide, and dimethyl sulfoxide. In this reaction, calcium carbonate or the like may be added as a deoxidizing agent to remove by-produced hydrogen halide.
The compounding ratio of the compound of general formula (9) and the halogen is not particularly limited and is appropriately selected within a wide range, but usually the latter is 2 to 5 times the former by mole, preferably 2
It is preferable to use up to 3 times the molar amount. The reaction is usually 0~
It is best to carry out the reaction at 50°C, and the reaction is usually completed in about several hours to 24 hours. The reaction for obtaining the compound of general formula (1a) from the compound of general formula (10) is preferably carried out in a solvent in the presence of a basic compound. As the basic compound, a wide variety of known compounds can be used, such as alkali metal hydroxides or alkaline earth metal hydroxides such as sodium hydroxide, potassium hydroxide, and calcium hydroxide. The amount of the basic compound used is not particularly limited and can be selected within a wide range,
Generally, it is preferable to use the compound in an amount ranging from 2 times the mole to a large excess amount relative to the compound of general formula (10). The reaction is usually 50 to 150
The reaction is preferably carried out at a temperature of 70 to 120°C, and the reaction is completed in about 1 to 12 hours. In Reaction Scheme-2 detailed above, the compound of general formula (3) used in the production of the compound of general formula (1c) includes some new compounds, and this compound can be used, for example, in the following reaction process. It is manufactured according to the method of Equation-7. Reaction formula-7 [In the formula, A and X ³ are the same as above. X ⁴ represents a halogen atom. ] The reaction between the oxindole of general formula (11) and the compound of general formula (12) is generally called a Friedel-Crafts reaction, and is usually carried out in the presence of a Lewis acid in a solvent. As solvents, those commonly used in reactions of this type are used, such as carbon disulfide, nitrobenzene, chlorobenzene, dichloromethane, dichloroethane, trichloroethane,
Tetrachloroethane etc. can be used. Any conventional Lewis acid can be suitably used, such as aluminum chloride, zinc chloride, iron chloride, tin chloride, boron tribromide, boron trifluoride, concentrated sulfuric acid, and the like. The amount of Lewis acid to be used may be determined as appropriate, but is usually about 2 to 6 times the mole of oxindole (11), preferably about 2 to 4 times the mole of oxindole (11). The amount of the compound of general formula (12) to be used relative to oxindole (11) is usually at least an equimolar amount, preferably an equimolar amount to twice the molar amount. The reaction temperature is appropriately selected, but it is usually about 0 to 120°C, preferably about 0 to 70°C. Although the reaction time varies depending on the raw materials, catalyst, reaction temperature, etc., it cannot be stated unconditionally, but the reaction is usually completed in about 0.5 to 6 hours. Among the compounds of the present invention, compounds in which R represents a hydrogen atom can be obtained by dephenyl-lower alkylation and de-lower alkanoylation of compounds in which R is a phenyl lower alkyl group or a lower alkanoyl group, respectively. The de-phenyl lower alkylation reaction is a conventional de-N removal reaction.
- phenyl lower alkylation reaction conditions. Specifically, the reaction is carried out in a suitable solvent in the presence of a catalytic reduction catalyst such as palladium-carbon, palladium-black, etc. at 0° C. to around room temperature for about 0.5 to 3 hours. Examples of the solvent that can be used include water, lower alcohols such as methanol, ethanol, and isopropanol, ethers such as dioxane and tetrahydrofuran, and acetic acid. The de-lower alkanoylation reaction is carried out in the same manner as a normal hydrolysis reaction. For example, in water or alcohol such as methanol or ethanol, inorganic bases such as sodium hydroxide or potassium hydroxide, or hydrochloric acid,
It is carried out using an acid such as hydrobromic acid. The above-mentioned dephenyl lower alkylation reaction can also be carried out under the same conditions as the above-mentioned de-lower alkanoylation reaction. The oxindole derivative represented by the general formula (1) in the present invention can be easily formed into an acid addition salt by reacting with a pharmaceutically acceptable acid. Examples of the acid include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid, oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid,
Organic acids such as benzoic acid may be mentioned. Further, among the oxindole derivatives represented by the general formula (1) of the present invention, a compound having an acidic group can be easily formed into a salt by reacting with a pharmaceutically acceptable basic compound. Examples of the basic compound include sodium hydroxide,
Potassium hydroxide, calcium hydroxide, sodium carbonate, potassium hydrogen carbonate, etc. can be mentioned. The target compounds obtained in each step can be easily isolated and purified by conventional separation means. Examples of the separation means include solvent extraction, dilution, recrystallization, column chromatography, preparative thin layer chromatography, and the like. Incidentally, the present invention naturally also includes optical isomers. The compound of general formula (1) is usually used in the form of a common pharmaceutical preparation. The formulation is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and lubricants. Various forms of this pharmaceutical preparation can be selected depending on the therapeutic purpose, and representative examples include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, and injections ( solutions, suspensions, etc.). When forming tablets, a wide variety of carriers conventionally known in this field can be used, such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, etc. Excipients, water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, binders such as polyvinylpyrrolidone, dry starch, sodium alginate, agar powder, laminaran powder , sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch,
Disintegration inhibitors such as lactose, white sugar, stearin, cocoa butter, hydrogenated oil, etc., absorption enhancers such as quaternary ammonium bases and sodium lauryl sulfate, humectants such as glycerin and starch, starch, lactose, and kaolin. Examples include adsorbents such as bentonite and colloidal silicic acid, purified talc, stearate, boric acid powder, and lubricants such as polyethylene glycol. Furthermore, the tablets may be coated with a conventional coating, if necessary, such as sugar-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, film-coated tablets, double tablets, or multilayer tablets. When forming into a pill form, a wide variety of carriers conventionally known in this field can be used, such as excipients such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, kaolin, and talc, powdered gum arabic, Binders such as tragacanth powder, gelatin, and ethanol,
Examples include disintegrants such as laminaran agar.
When forming into a suppository, a wide variety of conventionally known carriers can be used, such as polyethylene glycol, cacao butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, and the like. When prepared as injections, solutions and suspensions are preferably sterilized and isotonic with blood, and when forming these solutions, emulsions, and suspensions, this agent is used as a diluent. All those commonly used in the field can be used, including water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, and the like. In this case, the cardiotonic agent may contain a sufficient amount of salt, glucose, or glycerin to prepare an isotonic solution, and a conventional solubilizing agent,
Buffers, soothing agents, etc. may be added. Furthermore, coloring agents, preservatives, perfumes, flavoring agents, sweeteners, etc., and other pharmaceuticals may be included in the pharmaceutical preparation, if necessary. The amount of the compound of general formula (1) to be contained in the cardiotonic agent of the present invention is not particularly limited and can be appropriately selected within a wide range, but is usually 1 to 70% by weight, preferably 1 to 30% by weight based on the total composition. %. There are no particular restrictions on the method of administering the cardiotonic agent of the present invention,
Various formulation forms, patient age, gender and other conditions,
It is administered according to the patient's severity. For example, tablets, pills, solutions, suspensions, emulsions, granules, and capsules are administered orally. In the case of an injection, it is administered intravenously alone or mixed with a normal replacement fluid such as glucose or amino acids, and furthermore, if necessary, it is administered alone intramuscularly, intradermally, subcutaneously, or intraperitoneally. Suppositories are administered rectally. The dosage of the cardiotonic agent of the present invention depends on the usage, the age of the patient,
The amount of the compound of general formula (1), which is the active ingredient, is usually about 0.1 to 10 mg per 1 kg of body weight per day, although it is appropriately selected depending on gender and other conditions, the severity of the disease, etc. It is also possible to contain 1 active ingredient in a dosage unit form.
It is best to contain ~200mg. Examples Reference examples and examples are listed below. Reference Example 1 Add 45 g of 5-chloroacetyloxindole to 180 ml of pyridine, and heat and stir at 80° C. for 1 hour. After the reaction was completed, the crystals were allowed to cool, collected, washed with acetone, and recrystallized with methanol.
5-α-pyridinium acetyloxindole chloride in the form of colorless needles with a mp of 300°C or higher is obtained.
The obtained compound was dissolved in 17.2 g of sodium hydroxide and water.
Pour into 600ml solution and heat and stir at 70-80℃ for 30 minutes. After the reaction is completed, the mixture is allowed to cool and the reaction solution is made acidic with concentrated hydrochloric acid. Remove the precipitated crystals and wash with water. Dimethylformamide (DMF) - 28g recrystallized from water
5-carboxyoxindole is obtained. mp.300℃ or higher colorless powder crystal Elemental analysis value as C ₉ H ₇ O ₃ N C H N Calculated value 61.01 3.98 7.90% Actual value 61.12 3.81 8.10% Reference example 2 α-chloroacetyl chloride 47.4g, pulverized anhydrous chloride 80.0g of aluminum was heated with carbon disulfide under ice cooling.
Suspend in 100 ml, add 26.6 g of oxindole while stirring vigorously, and reflux for about 3 hours. After the reaction, the solvent was removed under reduced pressure and the residue was dissolved in ice-water 1
Disassemble and leave to cool for a while. The precipitated crystals are collected, washed with water, methanol, and then ether, and then dried. 15g of 5-(α-chloroacetyl)
Obtain oxindole. mp.246.5-247.0℃ Example 1 0.88g of 5-carboxyoxindole
Add 0.82 ml of triethylamine to 10 ml of DMF solution while stirring on ice, and add 0.77 ml of isobutyl chloroformate.
ml and stirred at the same temperature for 1 hour. After that, 1
-Add 1.1 g of benzylpiperazine and stir overnight at room temperature. After the reaction, DMF was distilled off under reduced pressure.
Add aqueous sodium hydrogen carbonate solution to the residue and extract with chloroform. Wash with water, dry with magnesium sulfate, and remove chloroform under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride: methanol = 50:1), and then recrystallized from isopropanol to obtain 0.7 g of 5-(4-benzyl-1-piperazinylcarbonyl). ) to obtain oxindole. mp.151-153°C Colorless prismatic crystals The compounds shown in Table 1 below are obtained in the same manner as in Example 1 using appropriate starting materials.

【table】

[Table] Example 9 1 g of 5-(1-piperazinylcarbonyl)oxindole hydrochloride was suspended in 20 ml of dichloromethane, 1.32 ml of triethylamine was added, and the mixture was stirred for 10 minutes under ice cooling.
After stirring for a minute, 0.3 ml of acetyl chloride is added, and the mixture is further stirred at the same temperature for 30 minutes. After the reaction is completed, the solvent is distilled off under reduced pressure, water is added to the residue, and the mixture is made alkaline with sodium carbonate. Extract with dichloromethane, wash with water and saturated saline, and dry over magnesium sulfate. Dichloromethane was distilled off under reduced pressure, and the resulting residue was subjected to silica gel column chromatography (eluent: methylene chloride: methanol = 50:1).
Refined at. Recrystallization from isopropanol yields 0.3 g of 5-(4-acetyl-1-piperazinylcarbonyl)oxindole. mp.181-182°C Colorless powder crystal Example 10 The compound of Example 4 is obtained in the same manner as in Example 9 using appropriate starting materials. Example 11 A mixture of 0.8 g of β-chloropropiophenone, 1.0 g of sodium iodide, and 20 ml of acetone was
Heat to reflux for an hour. After distilling off the acetone, the residue
DMF10ml, 5-(1-piperazinylcarbonyl)
Add 1.0 g of oxindole hydrochloride and 1.5 ml of triethylamine, and react at room temperature for 3 hours. After the reaction is complete, DMF is distilled off under reduced pressure and the residue is washed with water.
The obtained residue was subjected to silica gel column chromatography (eluent: dichloromethane: methanol =
Purify at 100:5). Recrystallized from methanol-dichloromethane to give 0.4 g of 5-[4(2-benzylethyl)-1-piperazinylcarbonyl]
Obtain oxindole. mp.208-210℃ Colorless prismatic crystal Example 12 1.0 g of 5-(1-piperazinylcarbonyl)oxindole hydrochloride, 1.2 g of DBU and 0.73 g of isobutyl bromide were suspended in 15 ml of acetonitrile and heated for 6 hours. Reflux. Then, add 0.6 ml of triethylamine and isobutyl bromide.
Add 0.73 g and heat under reflux for an additional 8 hours. The reaction mixture was poured into saturated sodium bicarbonate solution and extracted with chloroform. The chloroform layer is washed with saturated saline and dried over sodium sulfate. The solvent was distilled off, and the resulting residue was purified by silica gel column chromatography (eluent: dichloromethane:methanol = 20:1). The mixture was converted into a hydrochloride with acetone-concentrated hydrochloric acid and recrystallized from ethanol-methanol to obtain 0.39 g of 5-(4-isobutyl-1-piperazinylcarbonyl)oxindole hydrochloride. mp.285-289°C (decomposition) Colorless needle crystals Example 13 Using appropriate starting materials, the compounds of Examples 6 and 8 above and Example 17 below are obtained in the same manner as in Example 11 or 12. Example 14 5-(α-chloroacetyl)oxindole
1.0 g of 3,4-dimethoxybenzoyl-1-piperazine and 0.8 ml of triethylamine are suspended in 10 ml of acetonitrile and stirred at room temperature for 17 hours. After removing insoluble materials and concentrating the mother liquor, it was poured into saturated aqueous sodium bicarbonate and extracted with chloroform. The chloroform layer was washed with water and saturated brine in that order, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue is purified by silica gel column chromatography (eluent: chloroform:methanol = 20:1). Make the hydrochloride with methanol-concentrated hydrochloric acid.
Recrystallize from ethanol-methanol to give 5-{2
-[4-(3,4-dimethoxybenzoyl)-1-
0.34 g of piperazinyl[acetyl]oxindole hydrochloride was obtained. mp.218-221°C (decomposition) Pale yellow needle crystals Using appropriate starting materials, the compounds shown in Table 2 below are obtained in the same manner as in Example 14.

【table】

[Table] Example 23 5-[2-(1-piperazinyl)acetyl]oxindole dihydrochloride 1.0 g, potassium carbonate
0.63 g of m-chlorobenzoyl chloride in a suspension solution of 5 ml of water and 10 ml of acetone under ice-cooling and stirring.
Add dropwise 2 ml of acetone solution and stir at the same temperature for 1.5 hours. After the reaction is complete, the reaction mixture is poured into ice water and extracted with chloroform. The chloroform layer was washed with water and saturated brine in that order, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. After purifying the obtained residue by silica gel column chromatography (eluent: chloroform:methanol = 20:1),
Recrystallized from ethanol-chloroform to give 5-
0.34 g of {2-[4-(3-chlorobenzoyl)-1-piperazinyl]acetyl}oxindole is obtained. mp.215-218°C (decomposition) Pale yellow prismatic crystals Example 24 The compounds of Examples 14-16, 18, 19 and 22 are obtained in the same manner as in Example 23 using appropriate starting materials. Example 25 11 g of 5-[2-(4benzyl-1-piperazinyl)acetyl]oxindole and 10% Pd-
1 g of C is suspended in a mixed solvent of 100 ml of ethanol and 5 ml of water, and hydrogenolysis is carried out at room temperature and pressure. After the reaction is completed, the catalyst is removed and the liquid is concentrated. The obtained residue was recrystallized from methanol-water to give 5-
4.0 g of [2-(1-piperazinyl)acetyl]oxindole dihydrochloride is obtained. mp.232-235°C (decomposition) Colorless prismatic crystals Example 26 The compound of Example 2 is obtained in the same manner as in Example 25 using appropriate starting materials. Example 27 5-carboxyoxindole 0.93g,
1.3 g of DCC and 1.1 g of benzylpiperazine are suspended in 10 ml of dioxane and stirred at 60-70°C for 5 hours. After the reaction is complete, the solvent is distilled off, and ether is added to remove the precipitated crystals. After concentrating the mother liquor, the residue is dissolved in chloroform and washed with water and saturated brine. After drying with sodium sulfate, the solvent is distilled off.
Recrystallization from isopropanol gives 300 mg of 5-(4-benzyl-1-piperazinylcarbonyl)oxindole. mp.151-153°C Colorless prismatic crystals Example 28 The compounds of Examples 2-8 are obtained in the same manner as in Example 27 using appropriate starting materials. Example 29 0.93 g of 5-carboxyoxindole and 0.8 ml of triethylamine are suspended in 10 ml of tetrahydrofuran (THF), and while stirring at room temperature, a solution of 1.0 g of diethyl chlorophosphate in 10 ml of THF is added dropwise, followed by stirring at room temperature for 3 hours. A solution of 1.1 g of benzylpiperazine in 10 ml of THF is added dropwise to this mixture, and the mixture is further stirred at room temperature for 10 hours. After the reaction was completed, the precipitated crystals were removed, the mother liquor was concentrated, and saturated sodium bicarbonate solution was poured into the residue.
Extract with chloroform. The organic layer is washed with water and saturated brine, dried over sodium sulfate, and then the solvent is distilled off. Recrystallized from isopropanol to give 5-
(4-benzyl-1-piperazinylcarbonyl)
Obtain 1.01 g of oxindole. mp.151-153°C Colorless prismatic crystals Example 30 The compounds of Examples 2-8 are obtained in the same manner as in Example 29 using appropriate starting materials. Example 31 1.76 g of 6-carboxyoxindole is suspended in 200 ml of methylene chloride, 2 ml of pyridine is added, and 1.4 g of thionyl chloride is added dropwise with stirring while maintaining the internal temperature at 0 to 20°C. 1 at the same temperature after the completion of dropping.
The mixture was stirred for an hour and a solution of 1.74 g of benzylpiperazine in 10 ml of methylene chloride was added dropwise. After the dropwise addition was completed, the mixture was stirred at room temperature for 4 hours. The reaction solution is thoroughly washed with an aqueous potassium carbonate solution, washed with water and diluted hydrochloric acid, dried over sodium sulfate, and then the solvent is distilled off. The obtained residue was isolated and purified by silica gel column chromatography (silica gel: Wako C-200, eluent: chloroform:methanol (V/V) = 20:1), and then recrystallized from isopropanol.
298 mg of 6-(4-benzyl-1-piperazinylcarbonyl)oxindole are obtained. mp.151-153°C Colorless prismatic crystals Compounds of Examples 2-8 are obtained in the same manner as in Example 31 using appropriate starting materials. Example 32 3.87 g of isobutyl chloroformate in 2 ml of dimethylformamide is added to a solution of 3.2 g of benzoic acid and 4 ml of triethylamine in 50 ml of dimethylformamide.
Drop the solution. After stirring at room temperature for 30 minutes, 5-(1
-piperazinylcarbonyl)oxindole
Drop a solution of 8.8 g in 3 ml of dimethylformamide,
Stir for 30 minutes at room temperature followed by 1 hour at 50-60°C.
The reaction mixture is poured into a large amount of saturated brine, extracted with chloroform, washed with water, and then dried. The solvent was distilled off and the residue was recrystallized from methanol to give 5-(4-
1.9 g of benzoyl-1-piperazinylcarbonyl)oxindole are obtained. mp.268-270°C Colorless prismatic crystals Compounds of Examples 3, 14-16, 18, 19, 21 and 22 are obtained in the same manner as in Example 32 using appropriate starting materials. Example 33 1.36 g of ethyl benzoate in 100 ml of ethanol,
0.5 g of sodium ethylate and 2.6 g of 5-(1-piperazinylcarbonyl)oxindole hydrochloride
g, in autoclave, 110 atm, 140~
React at 150°C for 6 hours. After cooling, the reaction solution was concentrated under reduced pressure, and the residue was dissolved in 200 ml of chloroform.
After sequentially washing with a 1% aqueous potassium carbonate solution, dilute hydrochloric acid and water, drying over sodium sulfate and distilling off the solvent, the resulting residue was subjected to silica gel column chromatography (silica gel: Wako C-200, eluent: chloroform: methanol). (V/V)=20:
1) and recrystallize the crude crystals from methanol to obtain 215 mg of 5-(4-benzoyl-1-piperazinylcarbonyl)oxindole. mp.268-270°C Colorless prismatic crystals Compounds of Examples 3, 14-16, 18, 19, 21 and 22 are obtained in the same manner as in Example 33 using appropriate starting materials. Example 34 1.2 g of benzoic acid and 3.0 g of 5-(1-piperazinylcarbonyl)oxindole hydrochloride were added to a mixed solvent of 20 ml of dioxane and 20 ml of methylene chloride, and N,N-dicyclohexyl was added under external ice cooling and stirring. A solution of 2.1 g of carbodiimide dissolved in 5 ml of methylene chloride is added dropwise while maintaining the temperature at 10 to 20°C. After dropping, stir at the same temperature for 3.5 hours. The precipitated crystals were removed, and the liquid was concentrated to dryness under reduced pressure. The obtained residue was dissolved in 100 ml of methylene chloride, and the organic layer was washed successively with a 5% aqueous hydrochloric acid solution, a 5% aqueous sodium bicarbonate solution, and water, and then dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was recrystallized from methanol to obtain 0.79 g of colorless prismatic crystals of 5-(4-benzoyl-1-piperazinylcarbonyl)oxindole. mp.268-270°C Using appropriate starting materials, the compounds of Examples 3, 14-16, 18, 19, 21 and 22 are obtained in the same manner as in Example 34. <Pharmacological test> Pentobarbital sodium salt is administered intravenously at a rate of 30 mg/Kg to an adult male and female mixed breed dog weighing 8 to 13 kg to anesthetize it. heparin sodium salt
After intravenous administration at a rate of 1000U/Kg, death was caused by exsanguination.
Remove the heart. The specimen mainly consists of papillary muscles and ventricular septum, and is perfused with blood from a donor dog at a constant pressure of 100 mmHg through a cannula inserted into the anterior septal artery. Donor dogs weighing 18 to 27 kg were anesthetized with pentobarbital sodium salt 30 mg/kg intravenously, and heparin sodium salt 1000 U/kg was administered intravenously.
Kg is administered intravenously. Using bipolar electrodes, stimulate the papillary muscles with a square wave at a voltage 1.5 times the threshold value (0.5 to 3 V), a stimulation width of 5 msec, and a stimulation frequency of 120 times per minute.
The resting tension of the papillary muscles is 1.5 g, and the generated tension of the papillary muscles is measured via a force displacement exchanger. The blood flow in the anterior septal artery is measured using an electromagnetic flowmeter. Records of generated tension and blood flow are recorded on an ink recorder. The details of this method have already been reported by Endo and Hashimoto (Am, J. Physiol, 218 , No.
pp. 1459-1463, 1970). The test compound is administered intra-arterially in a volume of 10-30 μ over 4 seconds. The inotropic effect of the test compound is expressed as a % change in the tension generated before drug administration. The effect on coronary blood flow is expressed as the change in absolute value (ml/min) from before administration. The results are shown in Table 3 below. Test Compound No. 1 5-(isobutyl-1-piperazinylcarbonyl)oxindole hydrochloride 2 5-[4-(2-phenoxyethyl)-1-piperazinylcarbonyl]oxindole 3 5-{2-[ 4-(3,4-dimethoxybenzoyl)-1-piperazinyl]acetyl}oxindole hydrochloride 4 5-[2-(4-benzyl-1-piperazinyl)acetyl]oxindole dihydrochloride 1
Hydrate 5 5-{2-[4-(3,4-methylenedioxybenzoyl)-1-piperazinyl]acetyl}
Oxindole hydrochloride 6 5-{2-[4-(4-methylbenzoyl)-1
-piperazinyl]acetyl}thioxindole quarter hydrate 7 5-{2-[4-(3-chlorobenzoyl)-1
-piperazinyl]acetyl}oxindole

[Table] Oral acute toxicity test This toxicity test was conducted for the above test compound No. 1, 5-(4
-isobutyl-1-piperazinylcarbonyl)oxindole hydrochloride was administered orally to male rats. As a result, the LD ₅₀ value of the above compound was 3000 mg/Kg or more. Almost the same results were obtained for other compounds of the present invention. From this, it can be said that the compound of the present invention does not show any serious problems in terms of toxicity at an effective dose for the treatment of heart diseases or at a dose higher than this. Formulation example 1 5-{2-[4-(3,4-dimethoxybenzoyl)
-1-Piperazinyl]acetyl}oxindole 5 mg Starch 132 mg Magnesium stearate 18 mg Lactose 45 mg Total 200 mg Tablets of the above composition were prepared in one tablet by a conventional method. Formulation Example 2 5-(4-benzoyl-1-piperazinylcarbonyl)oxindole 10mg Starch 127mg Magnesium stearate 18mg Lactose 45mg Total 200mg Tablets of the above composition were prepared in one tablet by a conventional method. Formulation example 3 5-{2-[4-(4-methylbenzoyl)-1-piperazinyl]acetyl}oxindole 500mg Polyethylene glycol (molecular weight: 4000) 0.3g Sodium chloride 0.9g Polyoxyethylene sorbitan 0.4g Monooleate metachloride Sodium sulfite 0.1g Methyl-parapene 0.18g Propyl-parapene 0.02g Distilled water for injection 100ml The above parapenes, sodium metabisulfite and sodium chloride are dissolved in the above distilled water at 80°C with stirring. The resulting solution was cooled to 40°C,
The compound of the invention, then polyethylene glycol and oxyethylene sorbitan monooleate were dissolved into the solution. Next, distilled water for injection is added to the solution to adjust the final volume, and the solution is sterilized by sterilization using a suitable filter paper, and then dispensed into ampoules in 1 ml portions to prepare injections. Formulation Example 4 5-[4-(2-phenoxyethyl)-1-piperazinylcarbonyl]oxindole 5 mg Starch 132 mg Magnesium stearate 18 mg Lactose 45 mg Total 200 mg Tablets of the above composition were prepared in one tablet by a conventional method. .

Claims (1)

[Claims] 1. General formula [In the formula, A represents a lower alkylene group. n represents 0 or 1. B represents a [Formula] group. R is a lower alkyl group, a phenoxy lower alkyl group,
A phenyl lower alkyl group, a benzoyl group which may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a lower alkoxy group and a halogen atom as a substituent on the phenyl ring, or a lower substituent on the phenyl ring. Indicates a benzoyl group having an alkylenedioxy group. ] A cardiotonic agent characterized by containing an oxindole derivative or a salt thereof as an active ingredient.